Cash, cash equivalents and marketable securities were $256.0 million as of December 31, 2022, which is anticipated to fund operations through 2024.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DYN:
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James
- Oppenheimer starts Dyne Therapeutics at Outperform with $34 price target
- Dyne Therapeutics initiated with an Outperform at Oppenheimer
- TipRanks ‘Perfect 10’ List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks